IX Biopharma Widens Net Loss by 12% in FY2024
IX Biopharma Widens Net Loss by 12% in FY2024
ix生物製藥在2024財年將淨虧損擴大了12%
Loss per share stood at $0.0141 from $0.0126 a year ago.Loss per share stood at $0.0141.
每股虧損爲0.0141美元。
iX Biopharma reported a net loss by 12% to $10.8m in FY2024 from $9.6m a year ago.
ix生物製藥(FY2024)的淨虧損爲1080萬美元，較去年同期的960萬美元增長了12%。
Revenue for the period slipped 1% to $5.95m from $5.91m in FY2023, whilst gross profit fell 55% to $1.04m from $2.32m in FY2023.
該期間的營業收入從FY2023年的591萬美元下降了1%至595萬美元，而毛利潤從FY2023年的232萬美元下降了55%至104萬美元。
Loss per share stood at $0.0141 from $0.0126 a year ago.
每股虧損爲0.0141美元，而去年同期爲0.0126美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間